"Although the Medicare physician fee schedule, which is typically the primary focus of many of our discussions, is what is used to determine physician payment for a service, payment for an ASC is governed by separate rules," write Jonathan Rubenstein, MD, and Mark Painter.
"When thinking about living with prostate cancer, this is really a couples' disease, and partners' unmet needs should be part of the conversation," says Stacy Loeb, MD.
"In our professional life, awareness of our bias in seeing patients based on their weight, color, age, literacy level, or social status is evident," writes Gopal H. Badlani, MD.
There was a statistically significant reduction in average daily micturition episodes and average daily urgency episodes with vibegron vs placebo.
The FDA is set to have a decision regarding the subcutaneous nivolumab formulation on or by December 29, 2024.
There were no adverse events, such as penile bruising, swelling, edema, allergy, or penile fracture, observed in patients treated with shockwave therapy plus platelet rich plasma.
“At 60 months, nadofaragene allowed bladder preservation in nearly half of the patients in the CIS cohort and two-thirds of patients in the Ta/T1 cohort,” said Vikram Narayan, MD.
Treatment with the Zenflow Spring System, a minimally invasive surgical therapy for the treatment of benign prostatic hyperplasia, does not cause negative sexual side effects.
“These findings support the use of 18F-PSMA-1007 PET/CT in the preoperative workflow of intermediate-and high-risk tumors,” said Nikhile Mookerji, MD.
Treatment with apalutamide and androgen deprivation therapy led to a 2-year biochemical recurrence-free survival rate of 100% in patients with high-risk, post-prostatectomy prostate cancer.
The clearance of the IND application for RAG-01 will initiate the launch of clinical trials in the US.
“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Findings from the study showed a clinical response rate of 76.4% and 78.4% at 6- and 12-months following activation of the device among patients in the intent-to-treat population.
“Given that non-Hispanic Black men were 4 years younger than the non-Hispanic White men, these data suggest that microvascular dysfunction may appear earlier in non-Hispanic Black men following a prostate cancer diagnosis," says Abigayle B. Simon.
